Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In Reply We thank Dr Santulli for his suggestions for additional analyses. We have now conducted a subgroup analysis according to history of diabetes, defined as treatment with any oral antidiabetic drug or insulin within the last year. Among patients with diabetes, the crude all-cause mortality rate was 11.0 deaths per 100 person-years among carvedilol users and 11.9 deaths per 100 person-years among metoprolol succinate users; the propensity score-adjusted hazard ratio (aHR) for all-cause mortality was 0.94 (95% CI, 0.76-1.17) comparing carvedilol vs metoprolol succinate. Among patients without diabetes, the mortality rates were 6.0 and 6.1 deaths per 100 person-years among carvedilol and metoprolol users, respectively, and the aHR was 1.00 (95% CI, 0.87-1.15). Data on history of hypertension are not available in this data set.
Pasternak B, Svanström H, Hviid A. β-Blockers in Diabetic Patients With Heart Failure—Reply. JAMA Intern Med. 2015;175(4):657. doi:10.1001/jamainternmed.2014.8017